Equities research analysts at StockNews.com initiated coverage on shares of iCAD (NASDAQ:ICAD - Get Free Report) in a research note issued to investors on Tuesday. The firm set a "sell" rating on the technology company's stock.
Several other analysts have also recently commented on ICAD. Laidlaw restated a "hold" rating on shares of iCAD in a research report on Thursday, April 17th. BTIG Research cut iCAD from a "buy" rating to a "neutral" rating in a research note on Wednesday, April 16th. Finally, Craig Hallum lowered iCAD from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th.
Read Our Latest Research Report on ICAD
iCAD Stock Performance
iCAD stock opened at $3.98 on Tuesday. iCAD has a one year low of $1.18 and a one year high of $4.02. The company has a 50-day simple moving average of $2.72 and a 200-day simple moving average of $2.41. The firm has a market capitalization of $109.24 million, a P/E ratio of -30.62 and a beta of 1.35.
iCAD (NASDAQ:ICAD - Get Free Report) last posted its earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%. The firm had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.54 million.
Institutional Trading of iCAD
Institutional investors have recently made changes to their positions in the stock. Parkman Healthcare Partners LLC acquired a new position in shares of iCAD during the first quarter valued at approximately $1,610,000. First Eagle Investment Management LLC increased its position in shares of iCAD by 6.1% during the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock valued at $1,311,000 after purchasing an additional 41,000 shares during the period. Informed Momentum Co LLC bought a new stake in shares of iCAD in the 1st quarter worth $593,000. Geode Capital Management LLC lifted its holdings in shares of iCAD by 6.6% in the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after buying an additional 17,059 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in iCAD during the first quarter valued at about $505,000. 24.61% of the stock is owned by institutional investors and hedge funds.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
